

Area Prescribing Group report

Date: No meeting held in April **Quorate:** N/A

The items in this report are supported by the area prescribing group (APG) and approval by NHS Cheshire and Merseyside Integrated Care Board (ICB) is detailed below.

All document links provided for any CMAPG recommendations, can be found via the [legacy Pan Mersey formulary](#). The [legacy Cheshire formulary](#) will also be updated to reflect these changes.

The legacy Cheshire formulary, and the legacy Pan Mersey APC website and formulary are now closed. Legacy documents are available by using the search function of the [Cheshire and Merseyside formulary](#).

CMAPG governance documents are hosted on the [Prescribing](#) section of the NHS Cheshire and Merseyside website.

Please note there may be items that have been considered by APG but not yet approved by NHS Cheshire and Merseyside ICB. Items will be reported in the month that they are approved.

Formulary and guidelines

Proposal	Notes	Financial implications	Approval
<p>Melatonin for the treatment of persistent chronic sleep disorders in children and adults</p> <p>Statement</p> <p>Prescribing Support Information</p> <p>RAG designation: Amber initiated</p> <p>APG subgroup: 20 Jan 2026</p> <p>APG: 06 Feb 2026</p>	<p>Statement and prescribing support information to harmonise melatonin RAG designation and prescribing recommendations across Cheshire and Merseyside.</p>	<p>The estimated cost of implementing melatonin for the treatment of persistent chronic sleep disorders in children and adults across Cheshire and Merseyside in 2026-27 is £170,000.</p>	<p>MOP: 19 February 2026, clinically supported by MOP group.</p> <p>ICB Executive Committee: 02 April 2026, approved by ICB Executive Committee.</p>

